Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy
{{output}}
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, however, their use is limited by heterogeneous and unpredictable immune-related adverse events (irAEs), which can progress to life-threatening conditions requiring intensive care unit (ICU... ...
